U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
The FDA approved Eli Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes, the fourth global approval following EMA, COFEPRIS and PMA actions. Approval rests on the QWINT Phase 3 program of over 3,400 patients, in which weekly Onswik met non-inferiority on A1C reduction versus daily glargine or degludec with a similar safety profile. The KwikPen launches in the U.S.
Key figures
- Drug Name
- Onswik (insulin efsitora alfa-gobe)
- Phase Of Trial
- Phase 3
- Qwint enrollment
- 3400
- Global approvals count
- 4
- Annual injections vs daily
- 52 vs 365
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.